Sep 22, 2026 07:00AM
Aug 26, 2026 07:00AM
Aug 26, 2026 07:00AM
Aug 3, 2026 07:00AM
May 18, 2026 07:00AM
Mar 2, 2026 07:00AM
Feb 12, 2026 07:00AM Compugen appoints Michele Holcomb to board of directors
Feb 12, 2026 07:00AM
Dec 17, 2025 07:02AM
Dec 17, 2025 07:00AM
Nov 10, 2025 07:00AM
Oct 17, 2025 10:00AM
Oct 17, 2025 10:00AM
Oct 13, 2025 07:00AM Compugen to present COM701 ovarian cancer data at ESMO 2025
Oct 13, 2025 07:00AM
Aug 6, 2025 07:00AM
Jul 21, 2025 07:00AM
Jun 9, 2025 08:00AM
Jun 1, 2025 09:00AM
May 19, 2025 07:00AM
May 13, 2025 07:04AM Compugen (CGEN) Announces Leadership Transitions Effective September 2025
May 13, 2025 07:00AM
Mar 4, 2025 07:00AM
Feb 26, 2025 07:00AM
Jan 30, 2025 11:00PM
Jan 8, 2025 07:00AM
Nov 27, 2024 07:03AM
Nov 27, 2024 07:00AM Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies
Nov 12, 2024 07:00AM
Nov 11, 2024 07:00AM
Nov 5, 2024 09:00AM
Oct 29, 2024 07:00AM
Oct 7, 2024 07:00AM
Sep 9, 2024 07:00AM
Aug 29, 2024 07:00AM Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Aug 6, 2024 07:00AM
Jul 29, 2024 07:00AM
Mar 5, 2024 07:00AM
Dec 19, 2023 07:01AM
Dec 19, 2023 07:00AM
Nov 6, 2023 07:05AM
Nov 6, 2023 07:00AM Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy
Feb 27, 2023 07:00AM
Feb 14, 2023 07:00AM
Dec 6, 2022 07:00AM
Dec 1, 2022 07:09AM
Dec 1, 2022 07:00AM
Nov 7, 2022 08:05AM
Nov 7, 2022 08:04AM Compugen (CGEN) Reports CLM701 Induces Potent Immune Activation in MSS-CRC Patients
Nov 7, 2022 08:00AM

334,268 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All